文献速递前列腺增生与排尿功能障碍

良性前列腺增生药物治疗与眼表疾病风险:α受体阻滞剂与5α还原酶抑制剂的比较

Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-Blockers vs 5-Alpha Reductase Inhibitors.
PubMed 文献 · Urology · 2026-08-27

本回顾性队列研究利用去标识电子健康记录数据库,比较了接受α受体阻滞剂或5α还原酶抑制剂(5-ARI)治疗的良性前列腺增生(BPH)男性患者发生眼表疾病(OSD)的风险。结果显示,与α受体阻滞剂相比,5-ARI使用与更低的OSD风险相关(调整后HR 0.37;95%CI 0.19-0.65;95%CI 2.34-6.06)。

要点

  • 与α受体阻滞剂相比,5-ARI使用者的眼表疾病风险显著更低(调整后HR 0.37)。
  • α受体阻滞剂使用者发生眼表疾病的风险是未治疗BPH患者的3.77倍。
  • 对于有眼表疾病风险的BPH患者,选择5-ARI可能优于α受体阻滞剂。

核心结论

  • α受体阻滞剂与未治疗患者相比增加眼表疾病风险,而5-ARI使用与更低风险相关且与未治疗对照组无显著差异。

研究设计与样本

  • 回顾性队列研究,使用去标识电子健康记录数据库,纳入接受α受体阻滞剂或5-ARI治疗的BPH成年男性及未治疗BPH对照。

主要发现

  • 在2538例治疗男性(2303例α受体阻滞剂;235例5-ARI)中,发生235例眼表疾病事件。
  • 在三组模型(含未治疗患者)中,α受体阻滞剂使用与眼表疾病风险增加相关(HR 3.77;95%CI 2.34-6.06),而5-ARI使用无显著差异(HR 1.31;95%CI 0.67-2.82)。

临床怎么用

  • 对于有眼表疾病风险的BPH男性,临床决策时可考虑优先选用5-ARI而非α受体阻滞剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of incident ocular surface disease (OSD) among men treated with alpha-blockers vs 5-alpha reductase inhibitors (5-ARIs) for benign prostatic hyperplasia (BPH). METHODS: A retrospective cohort study using data from a de-identified electronic health record database was performed. Adult men diagnosed with BPH taking either an alpha-blocker or a 5-ARI were included, along with untreated BPH controls. OSD was defined using ICD-10-based concept sets for dry eye and related tear-film disorders. Time-to-event analyses were performed using Kaplan-Meier methods and Cox proportional hazards regression adjusting for age, diabetes, autoimmune disease, hypertension, hyperlipidemia, and PDE5i use. RESULTS: Among 2538 treated men (2303 alpha-blocker; 235 5-ARI), 235 OSD events occurred. Compared with alpha-blockers, 5-ARI use was associated with lower OSD risk in unadjusted (HR 0.47; 95% CI 0.27-0.82; P = .008) and adjusted analyses (HR 0.37; 95% CI 0.19-0.65; P = .001). Kaplan-Meier analysis demonstrated greater OSD-free survival among 5-ARI users (P = .008). In a three-group model including untreated patients, alpha-blocker use was associated with increased OSD risk vs no treatment (HR 3.77; 95% CI 2.34-6.06), while 5-ARI use was not (HR 1.31; 95% CI 0.67-2.82). CONCLUSION: Alpha-blockers were associated with increased OSD risk relative to untreated patients. Compared with alpha-blockers, 5-ARI use was associated with lower OSD risk and was not significantly different from untreated controls. These findings may inform therapeutic decision-making, particularly in men at risk for OSD.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ahmed Z, Chawareb EA, Hammad MAM, et al. Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-Blockers vs 5-Alpha Reductase Inhibitors. Urology. 2026. PMID: 42660325. doi:10.1016/j.urology.2026.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。